[1] SCHAPIRA A H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease[J]. Lancet Neurol, 2008, 7(1): 97-109.[2] COOKSON M R,VAN DER BRUG M. Cell systems and the toxic mechanism (s) of α-synuclein[J]. Exp Neurol, 2008, 209(1): 5-11.[3] YACOUBIAN T A,STANDAERT D G. Targets for neuroprotection in Parkinson's disease[J]. Biochim Biophys Acta, 2009, 1792(7): 676-687.[4] FRITSCH T, SMYTH K A, WALLENDAL M S, et al. Parkinson disease: Research update and clinical management[J]. South Med J, 2012, 105(12): 650-656.[5] PHANI S,LOIKE J D, PRZEDBORSKI S. Neurodegeneration and inflammation in Parkinson's disease[J]. Parkinson Relat Disord, 2012, 18 (1): 207-209.[6] KHANDELWAL P J, HERMAN A M, MOUSSA C E. Inflammation in the early stages of neurodegenerative pathology[J]. J Neuroimmunol, 2011, 238(1-2): 1-11.[7] NIRANJAN R. The Role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: Focus on astrocytes[J]. Molecular Neurobiol, 2013,17(3): 1-11.[8] DELEIDI M,GASSER T. The role of inflammation in sporadic and familial Parkinson's disease[J]. Cell Mol Life Sci, 2013, 70(22): 4259-4273.[9] POTT GODOY M C, TARELLI R, FERRARI C C, et al. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease[J]. Brain, 2008, 131(7): 1880-1894.[10] KIM H S,SUH Y H. Minocycline and neurodegenerative diseases[J]. Behav Brain Res, 2009, 196(2): 168-179.[11] CORBETT G T,ROY A,PAHAN K. Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: Implications for neuronal self-defense[J]. J Immunol, 2012, 189(2): 1002-1013.[12] LOFRUMENTO D D, NICOLARDI G, CIANCIULLI A, et al. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses[J]. Innate Immun, 2014, 20(3): 249-260.[13] WANG X, CHEN S, MA G, et al. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca²⁺ disturbance in microglia activation-mediated dopaminergic cell degeneration[J]. Mech Ageing Dev, 2005, 126(12): 1241-1254.[14] HOFMANN K W, SCHUH A F S, SAUTE J, et al. Interleukin-6 serum levels in patients with Parkinson's disease[J]. Neurochem Res, 2009, 34(8): 1401-1404.[15] BICK R J, POINDEXTER B J, KOTT M M, et al. Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells[J]. Brain Res, 2008, 121(7): 203-212.[16] KLEGERIS A, GIASSON B I, ZHANG H, et al. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells[J]. FASEB J, 2006, 20(12): 2000-2008.[17] BEYNON A L, BROWN M R, WRIGHT R, et al. Ghrelin inhibits LPS-induced release of IL-6 from mouse dopaminergic neurones[J]. J Neuroinflam, 2013, 10(1): 40.[18] CHU K,ZHOU X,LUO B Y. Cytokine gene polymorphisms and Parkinson's disease: A meta-analysis[J]. Can J Neurol Sci, 2012, 39(1): 58-64.[19] RENTZOS M, NIKOLAOU C, ANDREADOU E, et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease[J]. Acta Neurol Scand, 2009, 119(5): 332-337.[20] JOHNSTON L C, SU X, MAGUIRE-ZEISS K, et al. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease[J]. Mol Ther, 2008, 16(8): 1392-1399.[21] XIN J, WAINWRIGHT D A, MESNARD N A, et al. IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection[J]. Brain Behav Immun, 2011, 25(5): 820-829.[22] KUTER K, KOLASIEWICZ W, GOLEMBIOWSKA K, et al. Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats[J]. Pharmacol Rep, 2011, 63(6): 1383-1392.[23] SCHWENKGRUB J, JONIEC-MACIEJAK I, SZNEJDER-PACHO LEK A, et al. Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease[J]. Pharmacol Rep, 2013, 65(1): 44-49.[24] LI D, HE Q, LI R, et al. Interleukin-10 promoter polymorphisms in Chinese patients with Parkinson's disease[J]. Neurosci Lett, 2012, 513(2): 183-186.[25] RENTZOS M,ROMBOS A. The role of IL-15 in central nervous system disorders[J]. Acta Neurol Scand, 2012, 125(2): 77-82.[26] MEUER K, PITZER C, TEISMANN P, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease[J]. J Neurochem, 2006, 97(3): 675-686.[27] LIAO C H, CHEN S Y, KUO J S, et al. Reduction of motor disorder in 6-OHDA-induced severe parkinsonism rats by post treatment with granulocyte-colony stimulating factor[J]. Chin J Physiol(中国生理学报), 2013, 56(3): 147-154.[28] SONG S, SAVA V, ROWE A, et al. Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease[J]. Neurosci Lett, 2011, 487(2): 153-157.[29] MEUER K, PITZER C, TEISMANN P, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease[J]. J Neurochem, 2006, 97(3): 675-686.[30] SCHNEIDER A, KRUGER C, STEIGLEDER T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis[J]. J Clin Invest, 2005, 115(8): 2083-2098.[31] HENZE C, HARTMANN A, LESCOT T, et al. Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: Role of granulocyte macrophage colony-stimulating factor[J]. J Neurochem, 2005, 95(4): 1069-1077.[32] SCHABITZ W R, KRUGER C, PITZER C, et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF)[J]. J Cereb Blood Flow Metab, 2008, 28(1): 29-43.[33] KIM N K, CHOI B H, HUANG X, et al. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model[J]. Eur J Neurosci, 2009, 29(5): 891-900.[34] MANGANO E N, PETERS S, LITTELJOHN D, et al. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease[J]. Neurobiol Dis, 2011, 43(1): 99-112.[35] CHOUDHURY M E, SUGIMOTO K, KUBO M, et al. A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced Parkinsonism of rats[J]. Brain Behav, 2011, 1(1): 26-43.[36] KOSLOSKI L M, KOSMACEK E A, OLSON K E, et al. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice[J]. J Neuroimmunol, 2013, 265(1-2): 1-10.[37] WHITTON P S. Inflammation as a causative factor in the aetiology of Parkinson's disease[J]. Br J Pharmacol, 2007, 150(8): 963-976.[38] HARMS A S, BARNUM C J, RUHN K A, et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease[J]. Mol Ther, 2011, 19(1): 46-52.[39] BIALECKA M, KLODOWSKA-DUDA G, KURZAWSKI M, et al. Interleukin-10(IL-10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients[J]. Parkinson Relat Disord, 2008, 14(8): 636-640.[40] HIRSCH E C,HUNOT S. Neuroinflammation in Parkinson's disease: A target for neuroprotection[J]. Lancet Neurol, 2009, 8(4): 382-397.[41] AL-AMRI J S,HAGRAS M M,MOHAMED I M. Effect of epigallocatechin-3-gallate on inflammatory mediators release in LPS-induced Parkinson's disease in rats[J]. Indian J Exp Biol, 2013, 51(5): 357-362.[42] PETERSON A L,NUTT J G. Treatment of Parkinson's disease with trophic factors[J]. Neurotherapeutics, 2008, 5(2): 270-280.[43] BAQUET Z C,BICKFORD P C,JONES K R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta[J]. J Neurosci, 2005, 25(26): 6251-6259.[44] VON BOHLEN UND HALBACH O,MINICHIELLO L,UNSICKER K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra[J]. FASEB J, 2005, 19(12): 1740-1742.[45] KORDOWER J H, HERZOG C D, DASS B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys[J]. Ann Neurol, 2006, 60(6): 706-715.[46] HERZOG C D, DASS B, HOLDEN J E, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys[J]. Mov Disord, 2007, 22(8): 1124-1132.